Correlation between lopinavir plasma levels and lipid abnormalities in patients taking lopinavir/ritonavir

被引:56
作者
De Requena, DG
Blanco, F
Garcia-Benayas, T
Jiménez-Nácher, I
González-Lahoz, J
Soriano, V
机构
[1] Hosp Carlos III, Inst Salud Carlos III, Pharmacol Unit, Madrid, Spain
[2] Hosp Carlos III, Inst Salud Carlos III, Infect Dis Serv, Madrid, Spain
关键词
REVERSE-TRANSCRIPTASE INHIBITORS;
D O I
10.1089/108729103322395465
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Lopinavir (LPV)/ritonavir (RTV) used in combination, is a potent antiretroviral drug. However, its benefit is limited by its inherent effect on lipid metabolism, causing dislypemia in a large proportion of treated patients. Fasting triglyceride (TG) and cholesterol levels were assessed in 126 HIV-infected patients who initiated salvage therapy based on LPV/RTV. Both TG and cholesterol significantly increased from baseline to month 3. A positive correlation was found between the percentage increase in TG and LPV trough levels (r = 0.32; p = 0.003). Moreover, patients with TG elevations above the median (27%) showed higher LPV Ctrough levels than those with lower TG elevations (7.1 vs. 4.7 mug/ml, p = 0.004). In contrast, no correlation was found between LPV Ctrough and increases in cholesterol levels. Cholesterol elevations were positively correlated with RTV Ctrough concentrations (r = 0.32; p = 0.003).
引用
收藏
页码:443 / 445
页数:3
相关论文
共 11 条
[1]   Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients [J].
Benson, CA ;
Deeks, SG ;
Brun, SC ;
Gulick, RM ;
Eron, JJ ;
Kessler, HA ;
Murphy, RL ;
Hicks, C ;
King, M ;
Wheeler, D ;
Feinberg, J ;
Stryker, R ;
Sax, PE ;
Riddler, S ;
Thompson, M ;
Real, K ;
Hsu, A ;
Kempf, D ;
Japour, AJ ;
Sun, E .
JOURNAL OF INFECTIOUS DISEASES, 2002, 185 (05) :599-607
[2]   Clinical use of lopinavir/ritonavir in a salvage therapy setting: pharmacokinetics and pharmacodynamics [J].
Boffito, M ;
Arnaudo, I ;
Raiteri, R ;
Bonora, S ;
Sinicco, A ;
Di Garbo, A ;
Reynolds, HE ;
Hoggard, PG ;
Back, DJ ;
Di Perri, G .
AIDS, 2002, 16 (15) :2081-2083
[3]  
CALBOREANU A, 2003, 10 CROI BOST FEBR
[4]  
de Mendoza Carmen, 2002, HIV Clin Trials, V3, P304
[5]  
JOHNSON M, 2000, AIDS S, V14, P7
[6]  
MURPHY RL, 2001, AIDS, V15, P1
[7]  
PADILLA S, 2002, 42 ICAAC SAN DIEG SE
[8]  
PRADIER C, 2002, 6 INT C DRUG THER HI
[9]  
ROCKSTROH J, 2000, AIDS S, V14, P29
[10]  
SHAFRAN S, 2002, 6 INT C DRUG THER HI